Disability

GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine

STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical…

2 years ago

FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023

Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment MarketTORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma…

2 years ago

Oasis Cannabis Utilizing AI-Powered Budtender Offering Personalized Recommendations & ChatGPT Agent

LAS VEGAS, NV / ACCESSWIRE / August 8, 2023 / CLS Holdings USA, Inc. (OTCQB:CLSH)(CSE:CLSH), (the ''Company'' or ''CLS''), a…

2 years ago

Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"),…

2 years ago

Matia Mobility and Tamm Net Launch Online Portal for Insurance Prior Authorization Submissions

SALT LAKE CITY, Aug. 2, 2023 /PRNewswire/ -- Matia Mobility, a leading provider of innovative mobility solutions, today announced the…

3 years ago

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform – Insights From The Discussion

MELVILLE, NY / ACCESSWIRE / July 31, 2023 / Chronic back pain is a significant issue in the United States,…

3 years ago

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging…

3 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia…

3 years ago

Nalu Medical, Inc. Presents Important New Clinical Data for PNS and SCS at ASPN 2023

CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based neurostimulation company that has miniaturized neurostimulation implants for the management of…

3 years ago